图2. 基线有脑转移和基线无脑转移人群的PFS 此外，有基线脑转移的患者中，Adagrasib组的ORR高于多西他赛组（26.9% vs 2.8%）；在无基线脑转移的患者中，Adagrasib组的ORR也高于多西他赛组（33.6% vs 11.2%）。在有基线脑转移和无基线脑转移的患者中，Adagrasib组的中位DOR也更长，分别为7.4个月vs 5.4个月、8.3个月vs 5.4个月。
[1]B. Han, J. Lu, H. Trametinib plus anlotinib in non-G12C KRAS-mutant non-small cell lung cancer: A single-center, open-label, single-cohort study. ESMO 2024. Abstract 1306P.[2]F. Barlesi, W. Yao, M. Duruisseaux, et al. Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12. ESMO 2024. Abstract LBA57.[3]Tony S. K. Mok et al., KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.. JCO 42, LBA8509-LBA8509(2024).
